fda approval of frontline nivolumab/ipilimumab combo in rcc
Published 6 years ago • 921 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
0:52
dr. mckay on fda approval of nivolumab/ipilimumab in frontline rcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
0:43
dr. eng on the fda approval of nivolumab plus ipilimumab in crc
-
1:34
fda approves frontline nivolumab for advanced melanoma
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
0:51
dr. pal on the frontline approval of nivolumab and ipilimumab in mrcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
4:22
dr awad on the fda approval of perioperative nivolumab for resectable nsclc
-
8:26
front-line therapy with nivolumab and salvage nivolumab ipilimumab in patients with advanced rcc
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
1:05
nivolumab and ipilimumab combination in frontline mcrc
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
0:29
dr. mckay on fda approval of frontline cabozantinib in rcc
-
0:59
dr. weber on the fda approval for fixed-dose of nivolumab
-
0:37
dr. petrylak on fda approval of nivolumab in bladder cancer
-
0:46
fda approval of second-dosing schedule of nivolumab
-
6:56
fda approves tas-102, nivolumab breakthrough in rcc, two priority reviews, and more
-
1:40
dr. powles on fda approval of pembrolizumab plus axitinib in advanced rcc
-
7:03
ipilimumab/nivolumab for favorable-risk mrcc